Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;39(5):313-314.
doi: 10.1038/s41371-025-01004-w. Epub 2025 Apr 24.

British and Irish Hypertension Society response to 'RAAS inhibitors in pregnancy, breastfeeding and women of childbearing potential: a review of national and international clinical practice guidelines'

Luca Faconti  1 , Louise Abrams  2 , Bernadette Jenner  3 , Eduard Shantsila  4 , Sarah Partridge  5 , Ian B Wilkinson  3
Affiliations
Review

British and Irish Hypertension Society response to 'RAAS inhibitors in pregnancy, breastfeeding and women of childbearing potential: a review of national and international clinical practice guidelines'

Luca Faconti et al. J Hum Hypertens. 2025 May.

Abstract

In their review of clinical practice guidelines on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors, Greenlees and Delles call for more explicit advice on the use of these drugs among women of childbearing potential, during pregnancy and breastfeeding. In response, the British and Irish Hypertension Society (BIHS) highlight the key issues for clinicians to consider when prescribing RAAS inhibitors to hypertensive women and suggest areas where further research is needed.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Professor Adrian J.B. Brady has received honoraria from Daiichi-Sankyo, Amgen, Sanofi-Aventis, Bayer, MSD, and Novartis. Professor Phil Chowienczyk has an interest in Centron Diagnostics, a company that has produced technology for blood pressure measurement. Professor Jacob George has received grants and travel funding from Astra Zeneca, Novartis and Daiichi Sankyo, is on Advisory Boards for AstraZeneca, Menarini and Novartis, consulting fees from Roche and PwC and is a Principal Investigator for studies funded by AstraZeneca, Alnylam, Novartis, Esperion. Dr Pankaj Gupta has received research grants, lecture honoraria and funding for conference attendance from Sanofi-Aventis and Amgen, and consulting fees from Ionis Pharmaceuticals. Dr Spoorthy Kulkarni is a PhD student at the University of Cambridge funded by AstraZeneca and has attended scientific advisory boards for Viatris. Professor Terry McCormack has received lecture honoraria and/or consultation fees from AstraZeneca, Daichi-Sankyo, and Medtronic. He is a co-investigator in the Alnylam study Kardia 3. Professor Neil R Poulter has received lecture honoraria and/or consultation fees from several pharmaceutical companies that manufacture blood pressure lowering agents including AstraZeneca, Eva Pharma, Lri Therapharma, Napi, Pfizer, Servier and Sanofi-Aventis. Professor Ian B Wilkinson has received research grants from AstraZeneca, GSK and scientific advisory board consultation fees for Viatris, Astra Zeneca and Roche. Dr Louise Abrams, Dr Luca Faconti, Dr Andrew Jordan, Dr Bernadette Jenner, Dr Vikas Kapil, Dr Philip Lewis, Dr Sarah Partridge, Professor Peter Sever, Dr Eduard Shantsila, Dr Wayne Sunman and Dr Helen Warren have no competing interests to declare for this manuscript. Ethical approval: Ethical approval was not required for this work as it did not involve any human or animal studies.

References

    1. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Published 28 August 2019, Last updated: 21 November 2023. https://www.nice.org.uk/guidance/ng136.
    1. Medicines and Healthcare products Regulatory Agency. ACE inhibitors and angiotensin II receptor antagonists: not for use in pregnancy. Drug Saf. 2007;1:8.
    1. Hoeltzenbein M, Tissen-Diabaté T, Fietz AK, Zinke S, Kayser A, Meister R, et al. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - treatment or hypertension related? An observational cohort study. Pregnancy Hypertens. 2018;13:65–71. 10.1016/j.preghy.2018.04.022. - PubMed
    1. Ahmed B, Tran DT, Zoega H, Kennedy SE, Jorm LR, Havard A. Maternal and perinatal outcomes associated with the use of renin-angiotensin system (RAS) blockers for chronic hypertension in early pregnancy. Pregnancy Hypertens. 2018;14:156–61. 10.1016/j.preghy.2018.09.010. - PubMed
    1. UK Teratology Information Service. Use of angiotensin converting enzyme inhibitors in pregnancy. 2021;4. https://uktis.org/monographs/use-of-angiotensin-converting-enzyme-inhibi....

MeSH terms

Substances